Mobilizing monocytes to cross-present circulating viral antigen in chronic infection

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3766-3776

  Gehring, Adam J ^a   Haniffa, Muzlifah ^b,c   Kennedy, Patrick T ^d   Ho, Zi Zong ^a   Boni, Carolina ^e   Shin, Amanda ^c   Banu, Nasirah ^a   Chia, Adeline ^a   Lim, Seng Gee ^f   Ferrari, Carlo ^e   Ginhoux, Florent ^c   Bertoletti, Antonio ^a,g,h  

^a AGENCY FOR SCIENCE   (Singapore)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c AGENCY FOR SCIENCE   (Singapore)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

^h Dept Medicine Endocrinol Diabet   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS B SURFACE ANTIGEN; MEMBRANE ANTIGEN; VIRUS ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC PATIENT; CROSS PRESENTATION; DIFFERENTIATION; FLUORESCENCE MICROSCOPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; PRIORITY JOURNAL; B LYMPHOCYTE; BLOOD; CELL CULTURE; CELL PROLIFERATION; COCULTURE; DENDRITIC CELL; IMMUNOLOGY; T LYMPHOCYTE; VIROLOGY;

B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; CROSS-PRIMING; DENDRITIC CELLS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MONOCYTES; T-LYMPHOCYTES;

EID: 84883533046     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI66043     Document Type: Article

References (53)

1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64(1):51-68. (Pubitemid 30143840)
2. Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492-499.
3. Untergasser A, et al. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology. 2006;43(3):539-547.
4. Bohm W, et al. Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol. 1995;155(7):3313-3321.
5. Stober D, Trobonjaca Z, Reimann J, Schirmbeck R. Dendritic cells pulsed with exogenous hepatitis B surface antigen particles efficiently present epitopes to MHC class I-restricted cytotoxic T cells. Eur J Immunol. 2002;32(4):1099-1108. (Pubitemid 34428826)
6. Schirmbeck R, Bohm W, Melber K, Reimann J. Processing of exogenous heat-aggregated (denatured) and particulate (native) hepatitis B surface antigen for class I-restricted epitope presentation. J Immunol. 1995;155(10):4676-4684.
7. Schirmbeck R, Melber K, Reimann J. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation. Eur J Immunol. 1995;25(4):1063-1070.
8. Barnaba V, Franco A, Alberti A, Benvenuto R, Balsano F. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature. 1990;345(6272):258-260.
9. Lazdina U, et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J Gen Virol. 2003;84(pt 1):139-146. (Pubitemid 36113559)
10. Thimme R, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77(1):68-76. (Pubitemid 36004947)
11. Tavakoli S, et al. Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection. Clin Exp Immunol. 2008;151(1):61-70. (Pubitemid 350230996)
12. Gehring AJ, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011;55(1):103-110.
13. Di Pucchio T, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008;9(5):551-557. (Pubitemid 351560524)
14. Hoeffel G, et al. Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity. 2007;27(3):481-492. (Pubitemid 47418679)
15. Bachem A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med. 2010;207(6):1273-1281.
16. Jongbloed SL, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010;207(6):1247-1260.
17. Poulin LF, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med. 2010;207(6):1261-1271.
18. Haniffa M, et al. Human tissues contain CD141(hi) cross-presenting dendritic cells with functional homology to mouse CD103(+) nonlymphoid dendritic cells. Immunity. 2012;37(1):60-73.
19. Tan AT, et al. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol. 2008;82(22):10986-10997.
20. Kennedy P, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637-645.
21. Boni C, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):e963-e969.
22. Maini MK, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med. 2000;191(8):1269-1280. (Pubitemid 30227116)
23. Lopes AR, et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J Clin Invest. 2008;118(5):1835-1845. (Pubitemid 351632386)
24. Schurich A, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011;53(5):1494-1503.
25. Mohamadzadeh M, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med. 2001;194(7):1013-1020.
26. Beckebaum S, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol. 2002;104(2):138-150. (Pubitemid 35026224)
27. Beckebaum S, et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology. 2003;109(4):487-495. (Pubitemid 36930163)
28. Op den Brouw ML, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 2009;126(2):280-289.
29. Shimizu Y, Guidotti LG, Fowler P, Chisari FV. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol. 1998;161(9):4520-4529. (Pubitemid 28492022)
30. Tavakoli S, et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol. 2004;85(pt 10):2829-2836. (Pubitemid 39360025)
31. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL. Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. Hepatology. 2006;44(4):907-914. (Pubitemid 46489555)
32. van der Molen RG, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology. 2004;40(3):738-746.
33. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One. 2011;6(1):e15324.
34. Xie Q, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9. Microbes Infect. 2009;11(4):515-523.
35. Wu J, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology. 2009;49(4):1132-1140.
36. Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest. 2004;114(5):701-712. (Pubitemid 39578761)
37. Ebrahimkhani MR, Mohar I, Crispe IN. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology. 2011;54(4):1379-1387.
38. Limmer A, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med. 2000;6(12):1348-1354. (Pubitemid 32001018)
39. Hou W, et al. Viral infection triggers rapid differentiation of human blood monocytes into dendritic cells. Blood. 2012;119(13):3128-3131.
40. Tacke F, Ginhoux F, Jakubzick C, van Rooijen N, Merad M, Randolph GJ. Immature monocytes acquire antigens from other cells in the bone marrow and present them to T cells after maturing in the periphery. J Exp Med. 2006;203(3):583-597.
41. Boni C, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007;81(8):4215-4225. (Pubitemid 46586915)
42. Das A, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med. 2008;205(9):2111-2124.
43. Webster GJ, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78(11):5707-5719. (Pubitemid 38661658)
44. Dubsky P, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007;37(6):1678-1690. (Pubitemid 46939501)
45. Chatterjee B, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood. 2012;120(10):2011-2020.
46. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science. 2005;307(5715):1630-1634. (Pubitemid 40354746)
47. Carotenuto P, Artsen A, Niesters HG, Osterhaus AD, Pontesilli O. In vitro use of autologous dendritic cells improves detection of T cell responses to hepatitis B virus (HBV) antigens. J Med Virol. 2009;81(2):332-339.
48. Shi M, et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol. 2007;147(2):277-286. (Pubitemid 46096006)
49. Gowans EJ, et al. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53(4):599-607.
50. Fan Z, Huang XL, Borowski L, Mellors JW, Rinaldo CR. Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells. J Virol. 2001;75(9):4413-4419. (Pubitemid 32410155)
51. Lu W, Andrieu JM. In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol. 2001;75(19):8949-8956. (Pubitemid 32851899)
52. Van Gulck ER, et al. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol. 2008;82(7):3561-3573. (Pubitemid 351429932)
53. Xu D-Z, et al. Results of a phase III clinical trial with an HbsAg-HBIG Immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. In press.